Pretargeting based on the new generation of humanized, recombinant, trivalent anti-CEA × anti-HSG bsAbs named TF2 was shown to be safe for the treatment of metastatic CRC patients with the lutetium-177-labeled hapten IMP288 [64]. This evidence concerns the gene CEACAM5 and colorectal carcinoma.